Lucera Erick
SEC insider (Form 3/4/5 filer). CIK 0001697616. Chief Financial Officer at Dyne Therapeutics, Inc. (DYN) and 3 other issuers. 41 reported Form 4/5 transactions since Sep 2024; latest on Aug 13, 2026. Located in WALTHAM, MA.
Companies Lucera Erick has filed insider reports for
- Dyne Therapeutics, Inc. (DYN): Officer, Chief Financial Officer
- SAB Biotherapeutics, Inc. (SABS): Director
- Beyond Air, Inc. (XAIR): Director
- Editas Medicine, Inc. (EDIT): Officer, EVP, CHIEF FINANCIAL OFFICER
Lucera Erick
CIK: 0001697616
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (41 total)
- Aug 13, 2026DYN
Dyne Therapeutics, Inc.
SaleDirect1.8K shares at avg. $26.28$47K - Jun 25, 2026DYN
Dyne Therapeutics, Inc.
SaleDirect2.4K shares at avg. $20.37$48K - May 13, 2026DYN
Dyne Therapeutics, Inc.
SaleDirect1.4K shares at avg. $18.36$27K - Apr 1, 2026DYN
Dyne Therapeutics, Inc.
SaleDirect5.7K shares at avg. $18.64$107K - Feb 12, 2026DYN
Dyne Therapeutics, Inc.
AwardDirect65K shares- - Dec 16, 2025SABS
SAB Biotherapeutics, Inc.
AwardDirectStock option (right to buy)
150K shares- - Nov 4, 2025XAIR
Beyond Air, Inc.
DispositionDirectStock Options (Right to buy)
2K shares- - Nov 4, 2025XAIR
Beyond Air, Inc.
DispositionDirectStock Options (Right to buy)
2.3K shares- - Nov 4, 2025XAIR
Beyond Air, Inc.
AwardDirectStock Options (Right to buy)
2.3K shares- - Nov 4, 2025XAIR
Beyond Air, Inc.
AwardDirectStock Options (Right to buy)
2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 13, 2026 |  DYN Dyne Therapeutics, Inc. | Sale | 1,797 | $26.28 | $47,225 | Direct |
| Jun 25, 2026 | DYN Dyne Therapeutics, Inc. | Sale | 2,362 | $20.37 | $48,114 | Direct |
| May 13, 2026 | DYN Dyne Therapeutics, Inc. | Sale | 1,448 | $18.36 | $26,585 | Direct |
| Apr 1, 2026 | DYN Dyne Therapeutics, Inc. | Sale | 5,727 | $18.64 | $106,751 | Direct |
| Feb 12, 2026 | DYN Dyne Therapeutics, Inc. | Award | 65,000 | - | $0 | Direct |
| Dec 16, 2025 |  SABS SAB Biotherapeutics, Inc. | Award Stock option (right to buy) | 150,000 | - | - | Direct |
| Nov 4, 2025 |  XAIR Beyond Air, Inc. | Disposition Stock Options (Right to buy) | 2,000 | - | - | Direct |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | Disposition Stock Options (Right to buy) | 2,250 | - | - | Direct |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | Award Stock Options (Right to buy) | 2,250 | - | - | Direct |
| Nov 4, 2025 | XAIR Beyond Air, Inc. | Award Stock Options (Right to buy) | 2,000 | - | - | Direct |
1-10 of 41 transactions